Sanofi Appoints Paulo Fontoura as Global Head of R&D, Effective September 2026

Sanofi's R&D leadership structure shifts on September 1, 2026, when Paulo Fontoura, MD, PhD, FAAN, assumes the role of Executive Vice President, Global Head of Research & Development Pharma, a transition that carries direct implications for pipeline prioritization, CMC planning, and the regulatory affairs function he will now oversee. Fontoura reports to CEO Belén Garijo and joins the Executive Committee, based in Paris.

Fontoura succeeds Dr. Houman Ashrafian, who is departing to pursue an external opportunity after three years with the company. The incoming head brings over 25 years across academic medicine, translational science, and late-stage clinical development. His remit spans research, translational medicine, clinical development, and regulatory affairs, meaning CMC teams and regulatory leads should expect his strategic priorities to shape submission timelines and development-stage gate decisions across therapeutic areas.

His most recent role was Chief Medical Officer at Xaira Therapeutics, an AI-native biotechnology company applying generative artificial intelligence to drug discovery. Before Xaira, Fontoura spent more than 15 years at Roche, ultimately serving as Senior Vice President and Global Head of Clinical Development for Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases. During that tenure, his teams contributed to over 60 new molecular entities and secured more than 20 FDA and EMA first approvals and line extensions, including multiple breakthrough therapy designations.

For regulatory affairs leads, the profile is notable: Fontoura's track record is weighted toward late-stage portfolio management at scale, with direct accountability for breakthrough therapy pathways across multiple modalities. His AI-native biotech background at Xaira suggests familiarity with data-driven development models that increasingly intersect with 21 CFR Part 211 compliance requirements and ICH Q10-aligned quality systems as digital tools are integrated into development workflows.

Fontoura holds an MD and PhD from the New University of Lisbon, completed postdoctoral training in neuroimmunology at Stanford University, and has authored more than 80 peer-reviewed publications. He is a Fellow of the American Academy of Neurology.

The degree to which Fontoura accelerates or resequences Sanofi's late-stage pipeline will become measurable against the company's next regulatory submission disclosures following his September start date.

Source: Sanofi via GlobeNewswire, June 22, 2026.